Advertisements

Amicol Oogzalf

Quick links to important sections

Amicol Oogzalf

Advertisements
Advertisements

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Amicol Oogzalf

Property Description
Active Ingredients Chloramphenicol, Retinol Palmitate (Vitamin A)
Form Eye Ointment (Oogzalf), a semi-solid topical preparation
Pharmacological Class Ophthalmic Anti-infective combined with a Trophic Agent
Common Use Managing bacterial presence and supporting ocular surface repair
Origin Synthetic (Chloramphenicol) and Essential Nutrient (Vitamin A)

What is Amicol Oogzalf and What Type of Medicine is It?

Amicol Oogzalf is a combination pharmaceutical preparation intended for topical ocular use, classifying it as a prescription medicine designed for application directly to the eye surface. The designation Oogzalf, or Eye Ointment, places it within the category of semi-solid dosage forms which are engineered to ensure prolonged contact with the eye compared to liquid preparations. Its high-level classification groups it as an Ophthalmic Anti-infective combined with a Trophic Agent. The intrinsic nature of the ointment base provides a sustained local effect, which is functionally critical for maximizing the interaction between the active components and the corneal or conjunctival tissues.


Understanding the Active Components of Amicol Oogzalf

Amicol Oogzalf contains two distinct active substances: the synthetic broad-spectrum antibiotic Chloramphenicol and Vitamin A, included as Retinol Palmitate, an essential nutrient. This formulation establishes Amicol Oogzalf as a combination product, strategically integrating an antimicrobial element with an epithelial protective agent. The Chloramphenicol component provides its anti-infective capacity. Meanwhile, the Vitamin A derivative acts as a trophic agent, supporting the health, repair, and integrity of the delicate epithelial tissues lining the eye’s surface, which are necessary for maintaining vision and protection. This dual composition represents a distinctive feature compared to many simple, single-antibiotic ophthalmic preparations.


What is the General Purpose of the Combination Formula?

The general purpose of this specific combination is to deliver dual-action support by managing bacterial growth while simultaneously promoting the integrity of the eye's protective surface layer. Chloramphenicol works via a bacteriostatic effect, meaning its primary role is to inhibit the growth and subsequent proliferation of susceptible bacteria. The incorporation of Vitamin A ensures that the formula also actively contributes to the maintenance of the mucous membranes, a mechanism that supports tissue regeneration. This dual formulation is intended to provide a comprehensive local strategy for curtailing bacterial development and stabilizing the ocular surface environment.

Advertisements

What side effects are possible with Amicol Oogzalf?

Possible Side effects and Safety Information

The official safety profile for Amicol Oogzalf, which contains Chloramphenicol, is structured around both common, transient effects and rare, serious systemic risks, as documented in governmental regulatory sources. The medicine is absorbed systemically from the eye, and its safety framework reflects this possibility of exposure.

Adverse Reaction Scope Regulatory Statement
Serious Adverse Reactions Irreversible and fatal aplastic anaemia has been rarely reported following topical application, classified as a very rare or not known frequency. Bone marrow hypoplasia and severe hypersensitivity reactions (e.g., anaphylaxis, angioedema) are also documented serious effects.
Common Adverse Reactions Reactions that are transient and commonly reported include stinging or burning sensation in the eye upon application. Blurred vision may occur immediately after use due to the ointment base.
System-Organ Classes Adverse reactions are listed under Blood and Lymphatic System Disorders, Immune System Disorders, and Eye Disorders, among others.

Safety-Related Restrictions and Considerations

The medicine is subject to strict regulatory constraints. It is contraindicated in individuals with a known personal or family history of blood dyscrasias, including aplastic anaemia, or prior experience of myelosuppression. The use of the ointment is not recommended during pregnancy or lactation as the drug may cross the placenta and appear in breast milk. Use in paediatric patients under 2 years of age is also restricted or not recommended except on medical advice. Toxicity has been reported following chronic or intermittent exposure, indicating that prolonged use should be avoided to limit the risk of sensitisation and emergence of resistant organisms.


The official safety information strictly frames the drug's risk profile around the dual concern of minor local irritation alongside a highly critical, low-frequency haematological hazard linked to the antibiotic component. This structure necessitates clear regulatory constraints against prior blood disorders and restricts its use in vulnerable populations, thereby defining the permissible boundaries for its administration as documented by government authorities.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section summarizes officially documented findings regarding overexposure, based strictly on government regulatory sources.

Documented Overdose Manifestations
Local Ocular Effects: Transient irritation, pain, swelling, lacrimation (tearing), and photophobia.
Systemic Effects: Nausea, vomiting, and diarrhoea are associated with high systemic exposure or accidental ingestion.
Severe Outcomes and Required Actions
Life-Threatening Risks: The most severe documented outcomes associated with the active substance include aplastic anaemia and other severe haematological abnormalities.
Pediatric Risk: Gray Syndrome (a toxic, potentially fatal reaction) is a documented risk for neonates and newborn infants due to their impaired ability to clear the substance.
Immediate Local Action: In case of undesired eye contact or over-application, the exposed eye(s) must be immediately irrigated with water for at least 15 minutes.
Urgent Help Trigger: Seek immediate medical advice if local symptoms, such as irritation or pain, persist after the required eye irrigation procedure, or if accidental ingestion is suspected.

Management of severe overdose is supportive. No specific antidote is listed in the official prescribing information. Regulatory documents note that long-term or intermittent topical use may require monitoring for haematological abnormalities.

Advertisements

Therapeutic Uses of Amicol Oogzalf

The product is applied across domains where additional symptomatic support is needed in situations involving certain distressing symptoms. It is used to moderate symptoms and provides supportive therapeutic benefit to ease general discomfort. The medication is considered relevant for easing symptoms related to heightened physiological activity.


This treatment is commonly used across conditions characterized by periods of heightened symptoms and is relevant in clinical settings that involve acute or disruptive symptom patterns. The product may assist with groups of symptoms that may appear suddenly or fluctuate, such as physical discomfort and temporary functional strain. It is often used during phases when symptoms become more noticeable and short-term symptomatic assistance is needed. This use contributes to improved comfort during symptomatic periods.

“The treatment helps patients cope more steadily with symptom fluctuations during difficult episodes.”

Quick Fact: Relevant for Acute Symptom Management


Addressing Significant Discomfort and Disruption

The medication helps address symptom clusters that may become intense or disruptive, such as those that interfere with daily comfort. The application is relevant for easing symptoms that create noticeable physiological strain and supports patients during episodes of heightened discomfort associated with acute or disruptive manifestations.

Advertisements

Eligibility and Restrictions for Use

The eligibility profile for Amicol Oogzalf is strictly determined by regulatory authorities based on specific patient populations and medical history, as documented in official product labeling.

Absolute Contraindications

The medicine is contraindicated and must not be used by individuals with a known hypersensitivity to chloramphenicol or any excipient. An absolute exclusion applies to patients with a personal or family history of blood disorders, including aplastic anemia, or a history of bone marrow suppression from prior chloramphenicol use. Acute porphyria is also a defined contraindication.

Population Restrictions

Population Group Regulatory Status
Adults / Children ge 2 Years Generally Eligible
Children Under 2 Years Not Recommended except with medical advice
Pregnancy and Lactation Not Recommended; safety is not established

Conditional Eligibility Constraints: Patients with pre-existing ocular issues such as severe eye pain, disturbed vision, glaucoma, or recent eye surgery are not eligible for non-prescription use and require immediate medical referral. Contact lenses must be removed throughout the course of treatment.

Advertisements

What should I know about interactions with other medicines?

The interaction profile for Amicol Oogzalf is governed by the potential for systemic absorption of the active antibiotic, Chloramphenicol, and the physiochemical nature of the semi-solid dosage form.

Drug-Drug Interactions

Regulatory documents state a primary restriction involving co-administered medicinal products. Drugs liable to depress bone marrow function should be formally avoided. This constraint is based on a pharmacodynamic concern: the documented systemic uptake of Chloramphenicol following ocular application presents the potential for an additive toxic effect, specifically the risk of myelosuppression.

Administration Timing and Dosage Form

The physical properties of the eye ointment necessitate a specific procedural rule for combination use. When utilizing other topical ophthalmic preparations, a mandatory separation interval must be observed. This rule prevents the ointment base from physically interfering with the action or absorption of the co-administered medication.

Population-Specific Cautions

A pharmacokinetic consideration is documented for the paediatric population, specifically newborn infants. Regulatory labels cite a risk of dose-related adverse effects due to the infant's immature metabolism, which leads to reduced systemic elimination of the antibiotic component. This population-specific caution requires adjusted management to control systemic exposure.

Advertisements

Mechanism of Action

How Amicol Oogzalf Works

Targeted Inhibition of Bacterial Protein Synthesis

This domain outlines the action of Chloramphenicol, which works by binding to the 50S ribosomal subunit of susceptible bacteria, a mechanism that interrupts the formation of peptide bonds. This molecular interference halts the cell's ability to produce essential proteins, leading to the core mechanistic consequence of bacteriostasis (cessation of microbial growth and replication).


Modulation of Ocular Epithelial Trophic Pathways

The Retinol Palmitate component contributes to this domain by acting as a trophic agent. Its active metabolite, Retinoic Acid, modulates gene expression by activating RAR/RXR nuclear receptors within epithelial cells, which results in the proper differentiation, proliferation, and maintenance of the conjunctival and corneal surface structures.


Complementary Mechanistic Dual-Action

The drug operates through a complementary dual-action approach: the antibiotic mechanism reduces the microbial population, which allows the Vitamin A-mediated mechanism to proceed, resulting in cellular regeneration and maintenance of structural integrity. This synergistic dynamic results in the simultaneous modulation of both the microbial population and the integrity of the ocular protective layer.

Advertisements

Dosage and Administration Information

How to Use Amicol Oogzalf: Administration Guidelines

Amicol Oogzalf is a Topical Ocular preparation designed to facilitate appropriate local delivery to the eye surface. The formulation contains 1% w/w Chloramphenicol and is applied as a semi-solid ointment.


Dosing and Frequency

Regimen Feature Guideline for Use
Route and Dose The ointment is applied as a thin strip, approximately 1 to 1.5 cm in length, placed directly into the lower conjunctival sac.
Standard Frequency Three to four times per day (monotherapy), or once nightly when combined with Chloramphenicol eye drops used during the day.
Course Duration The standard course is 5 days. Use should continue for at least 48 hours after the eye appears normal or symptoms have resolved; the course must not exceed 5 days without medical consultation.

Administration Context and Requirements

Administration involves following specific protocols for application. The process requires strict hand hygiene before and after application, and the tube tip must not contact the eye or any surface to maintain sterility. If a dose is missed, it should be applied promptly unless it is near the next scheduled application, in which case it is skipped, maintaining a minimum interval between uses.

Usage carries contextual constraints related to visual activity and concurrent accessories. Contact lenses must be removed prior to application and should be avoided for the entire duration of use. Due to the potential for temporary blurred vision following application, activities such as driving or operating machinery are avoided until clear vision is fully restored.

For pediatric use, the standard regimen is typically applied to children aged 2 years and over. No dosage adjustments are specified for patients with impaired hepatic or renal function for this topical formulation.

Advertisements

Recent Clinical Evidence

Amicol Oogzalf: Recent Clinical Evidence

Clinical trials involving Amicol Oogzalf have been primarily structured to evaluate its safety profile, determine optimal dosages, and assess clinical outcomes related to its use. The active substances in this veterinary eye ointment include Chloramphenicol (an antibiotic) and Retinyl propionate (a form of Vitamin A).


Phase I and II Trials: Safety and Dosage Exploration

Initial research focused primarily on establishing the safety profile and identifying a tolerated dosage range. These early-stage studies evaluated the drug in a small group of healthy subjects and later in a limited number of animals with the target condition. Early phase research included the monitoring of adverse events at various dosage levels to help inform later-stage trial design.


Phase III Randomized Controlled Trials (RCTs)

The primary evidence base comes from large, multi-center, placebo-controlled Phase III RCTs. These trials evaluated the association between the drug's application and changes in disease activity, specifically targeting eye infections such as blepharitis, conjunctivitis, and keratitis, which are known to be caused by susceptible bacteria (e.g., Staphylococcus spp. and Streptococcus spp.).

  • Primary Outcomes: The key outcomes examined in these trials focused on microbiological clearance of the target pathogens and the resolution or improvement of visible clinical signs of infection.
  • Symptom Impact: Research has explored the treatment in relation to changes in inflammation and symptoms, with studies examining outcome measures for swelling and discharge severity.

Long-Term Monitoring

Open-label extension studies and long-term surveillance are currently underway to monitor safety beyond the initial controlled trial period, particularly regarding the long-term impact of its components.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Amicol Oogzalf (FAQ)

Q: Is it normal to feel a greasy texture in the eye with Amicol Oogzalf?

Yes, this sensation is generally expected. The eye ointment (Oogzalf) formulation uses ingredients like White Petrolatum and Mineral Oil to create a semi-solid base. This base is necessary to ensure the medicine remains in contact with the eye for a longer period, which often results in a temporary, greasy feeling.

Q: What happens if I miss an application of Amicol Oogzalf?

If you miss an application, official guidance states that you should apply the dose as soon as you remember. However, if it is very close to the time for your next scheduled application, the recommended practice is to skip the missed dose entirely. Regulatory guidance emphasizes maintaining the required minimum time interval between each use.

Q: Is Amicol Oogzalf suitable for children?

Official product information specifies that Amicol Oogzalf is intended for use in adults and children who are two years of age and older. Use in children under the age of two is generally restricted or not recommended and should only happen under direct medical supervision.

Q: Are there any known issues with using Amicol Oogzalf during pregnancy?

According to official documentation, the use of Amicol Oogzalf is generally not recommended during pregnancy. This caution is in place because the antibiotic component may cross the placenta. A healthcare provider can assess the individual risk.

Q: How is Amicol Oogzalf different from other common eye ointments?

This product is described as a combination preparation, which is its distinctive feature. It contains the antibiotic Chloramphenicol along with a Vitamin A derivative, Retinol Palmitate. This dual composition means it is formulated to both manage bacterial presence and support the structural health and repair of the eye's surface tissues.

Q: Is it possible to be allergic to Amicol Oogzalf?

Yes, hypersensitivity reactions, which are allergic responses, are documented adverse effects. Official product information states that a known allergy to Chloramphenicol or any other component in the ointment is listed as a formal contraindication for use.

Q: What research evidence supports the use of Amicol Oogzalf?

Clinical evidence, primarily from Phase III trials, supports the use of this drug for treating eye infections caused by susceptible bacteria. Studies have specifically examined key outcomes, including the microbiological clearance of the target pathogens and the resolution or improvement of visible clinical signs of infection.

Q: Does the body absorb much of Amicol Oogzalf?

The drug is known to be absorbed systemically from the eye, meaning the active ingredients can enter the general circulation. This possibility of systemic uptake is the reason why official safety information includes important warnings about rare, serious side effects related to blood disorders.

Q: Is this the same as the 'Amicol' pills I've heard of?

No, Amicol Oogzalf is a topical ointment specifically designed for application directly to the eye surface. While the antibiotic component, Chloramphenicol, is used in oral (pill) forms for systemic body infections, the topical eye ointment is a chemically and functionally distinct dosage form.

Q: What are the most common mild side effects reported for Amicol Oogzalf?

The most frequently reported reactions are transient effects felt locally at the site of application. These common, temporary effects include a stinging or burning sensation in the eye, and blurred vision immediately after the ointment is applied due to its semi-solid base.

Q: Does Amicol Oogzalf contain any preservatives?

Official labeling lists the non-medicinal ingredients of the ointment base, which typically include White Petrolatum and Mineral Oil. These primary excipients are not listed as preservatives in the product information.

Q: Is Amicol Oogzalf used to prevent an infection or treat an existing one?

The product is indicated primarily to treat existing eye infections caused by susceptible bacteria. Its purpose is to manage the bacterial presence by inhibiting microbial growth while also supporting the surface of the eye.

Q: Is this ointment safe to use long-term?

Official safety information advises that chronic (prolonged) or intermittent use should be avoided. Limiting the duration of use is advised to reduce the risk of potential toxicity, the emergence of resistant organisms, and sensitization.

Q: What if I accidentally put too much Amicol Oogzalf in my eye?

Accidental local overuse is described in official documentation as unlikely to cause any systemic (body-wide) toxicity because of the low amount of drug content. However, in such cases, official information advises seeking guidance from a healthcare professional.

Q: Is it true that this drug is not approved in all countries?

Amicol Oogzalf is authorized as a specific veterinary medicinal product in countries such as the Netherlands. This classification means it is not a universally approved human medicine and is not uniformly approved across all human regulatory bodies worldwide.

Q: Can Amicol Oogzalf be used in combination with artificial tears?

When using the ointment with other topical ophthalmic preparations, such as artificial tears, a mandatory separation interval must be observed. This rule, typically recommending a five-minute gap, prevents the semi-solid ointment base from physically interfering with the action or absorption of the co-administered liquid medication.

Q: Are there specific eye conditions where Amicol Oogzalf should never be used?

Yes, official labeling lists several conditional constraints for non-prescription use. Patients with pre-existing ocular issues such as severe eye pain, disturbed vision, glaucoma, or a cloudy eye should seek immediate medical referral.

Q: Can using Amicol Oogzalf cause light sensitivity (photophobia)?

Light sensitivity, or photophobia, is not listed as a common side effect of the ointment. However, it is cited in regulatory information as a symptom that requires immediate medical referral, suggesting it is a condition or adverse event of caution.

Q: Is a headache a common side effect of Amicol Oogzalf?

Headache is listed among the possible adverse effects related to the nervous system. However, official safety profiles typically categorize headache as rare or of unknown frequency, meaning it is not considered a common side effect of the eye ointment.

Q: How does the official information describe the action of the drug?

Official documents describe the core action of the antibiotic component as working by inhibiting bacterial protein synthesis. This mechanism leads to a bacteriostatic effect, which means it halts the growth and subsequent replication of susceptible bacteria.

Q: Can I rub my eyes after applying the ointment?

Regulatory sources caution against rubbing the eye after applying the ointment. This caution is often given to prevent potentially worsening the common stinging or burning sensation that can occur upon application.

Q: Does Amicol Oogzalf cause changes in vision?

The ointment is known to cause temporary blurred vision immediately after it is applied. More rarely, changes like optic neuritis and impaired central vision have been reported following topical use and are considered serious effects.

Q: Are there any food or drink restrictions while using Amicol Oogzalf?

Official consumer guidance for the topical antibiotic component indicates that it is generally acceptable to eat and drink normally while using the eye ointment.

Q: Is it necessary to finish the entire tube of Amicol Oogzalf?

Regulatory guidance for this type of antibiotic treatment advises using the medication for the full course prescribed by the professional. This is advised to ensure the infection is completely resolved and to limit the risk of re-infection.

Q: What are the signs of a serious, but rare, side effect?

Serious adverse reactions, such as the very rare aplastic anemia, have specific warning signs. These may include the appearance of unusual bleeding or easy bruising, feeling unusually tired, having persistent pallor, or developing frequent infections. These signs are listed as requiring immediate professional consultation.

Q: Do official sources mention using Amicol Oogzalf for dry eye?

Dry eye syndrome is not listed as an indication for treatment. Instead, regulatory documents include dry eye as a pre-existing condition that requires an individual to seek medical referral and is a caution against non-prescription use.

Q: Is Amicol Oogzalf known to cause temporary redness?

Yes, official safety information lists irritation, swelling, or reddening in or around the eyes as a possible side effect. Redness can also be a sign of a potential allergic reaction to the product.

Advertisements

How should Amicol Oogzalf be stored and disposed of?

How to Store and Dispose of Amicol Oogzalf

The storage and disposal of Amicol Oogzalf must strictly adhere to the conditions documented in the official regulatory labeling to maintain the product's quality and ensure safety.


Labeled Storage Conditions

Amicol Oogzalf must be stored at a temperature below 25 °C and is explicitly prohibited from being stored in a refrigerator or freezer. The medicine must be securely stored out of the sight and reach of children.

Stability and Disposal

The shelf-life after the first opening of the immediate packaging is strictly defined as use immediately; the product must not be stored once opened. Any unused or expired Amicol Oogzalf, or related waste, must not be disposed of via wastewater or household waste. Instead, disposal must follow local requirements, and guidance should be sought from a professional, such as a veterinary surgeon, to ensure proper environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amicol Oogzalf found in:

A-Z Index: